Skip to main content
PMC home page
Neurotherapeutics logoLink to Neurotherapeutics
. 2008 Apr;5(2):226–236. doi: 10.1016/j.nurt.2008.01.003

Neuroprotection for Huntington’s disease: Ready, set, slow

Steven M Hersch 1,✉, H Diana Rosas 2
PMCID: PMC2359156  NIHMSID: NIHMS45329  PMID: 18394565

Summary

The ultimate goal for Huntington’s disease (HD) therapeutics is to develop disease-modifying neuroprotective therapies that can delay or prevent illness in those who are at genetic risk and can slow progression in those who are affected clinically. Neuroprotection is the preservation of neuronal structure, function, and viability, and neuroprotective therapy is thus targeted at the underlying pathology of HD, rather than at its specific symptoms. Preclinical target discovery research in HD is identifying numerous distinct targets, along with options for modulating them, with some proceeding into large-scale efficacy studies in early symptomatic HD subjects. The first pilot studies of neuroprotective compounds in premanifest HD are also soon to begin. This review discusses the opportunities for neuroprotection in HD, clinical methodology in premanifest and manifest HD, the clinical assessment of neuroprotection, molecular targets and therapeutic leads, and the current state of clinical development.

Key Words: Huntington’s disease, neuroprotection, disease modification, neurogenetics, genetic testing, clinical trials, presymptomatic, premanifest

References

  • 1.Zhang X, Smith DL, Meriin AB, et al. A potent small molecule inhibits polyglutamine aggregation in Huntington’s disease neurons and suppresses neurodegeneration in vivo. Proc Natl Acad Sci U S A. 2005;102:892–897. doi: 10.1073/pnas.0408936102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Chopra V, Fox JH, Lieberman G, et al. A small-molecule therapeutic lead for Huntington’s disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. Proc Natl Acad Sci U S A. 2007;104:16685–16689. doi: 10.1073/pnas.0707842104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Kremer B, Goldberg P, Andrew SE, et al. A worldwide study of the Huntington’s disease mutation: the sensitivity and specificity of measuring CAG repeats. N Engl J Med. 1994;330:1401–1406. doi: 10.1056/NEJM199405193302001. [DOI] [PubMed] [Google Scholar]
  • 4.Myers RH, MacDonald ME, Koroshetz WJ, et al. De novo expansion of a (CAG)n repeat in sporadic Huntington’s disease. Nat Genet. 1993;5:168–173. doi: 10.1038/ng1093-168. [DOI] [PubMed] [Google Scholar]
  • 5.Goldberg YP, Kremer B, Andrew SE, et al. Molecular analysis of new mutations for Huntington’s disease: intermediate alleles and sex of origin effects. Nat Genet. 1993;5:174–179. doi: 10.1038/ng1093-174. [DOI] [PubMed] [Google Scholar]
  • 6.Dubinsky RM. No going home for hospitalized Huntington’s disease patients. Mov Disord. 2005;20:1316–1322. doi: 10.1002/mds.20589. [DOI] [PubMed] [Google Scholar]
  • 7.Bonelli RM, Wenning GK. Pharmacological management of Huntington’s disease: an evidence-based review. Curr Pharm Des. 2006;12:2701–2720. doi: 10.2174/138161206777698693. [DOI] [PubMed] [Google Scholar]
  • 8.Bonelli RM, Hofmann P. A systematic review of the treatment studies in Huntington’s disease since 1990. Expert Opin Pharmacother. 2007;8:141–153. doi: 10.1517/14656566.8.2.141. [DOI] [PubMed] [Google Scholar]
  • 9.Hersch SM, Ferrante RJ. Translating therapies for Huntington’s disease from genetic animal models to clinical trials. NeuroRx. 2004;1:298–306. doi: 10.1602/neurorx.1.3.298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Beal MF, Ferrante RJ. Experimental therapeutics in transgenic mouse models of Huntington’ s disease. Nat Rev Neurosci. 2004;5:373–384. doi: 10.1038/nrn1386. [DOI] [PubMed] [Google Scholar]
  • 11.Hersch S, Greenamyre J. Huntington’s Disease. In: Johnson R, Griffin J, editors. Current therapy in neurologic disease. 5th ed. St. Louis: Mosby-Year Book; 1997. pp. 275–279. [Google Scholar]
  • 12.Anderson KE, Marder KS. An overview of psychiatric symptoms in Huntington’s disease. Curr Psychiatry Rep. 2001;3:379–388. doi: 10.1007/s11920-996-0030-2. [DOI] [PubMed] [Google Scholar]
  • 13.Rosenblatt A, Ranen NG, Nance M, Paulsen J. A physician’s guide to the management of Huntington’s Disease. 2nd ed. New York: Huntington’s Disease Society of America; 1999. [Google Scholar]
  • 14.Simpson SA. Late stage care in Huntington’s disease. Brain Res Bull. 2007;72:179–181. doi: 10.1016/j.brainresbull.2006.10.022. [DOI] [PubMed] [Google Scholar]
  • 15.Vamos M, Hambridge J, Edwards M, Conaghan J. The impact of Huntington’s disease on family life. Psychosomatics. 2007;48:400–404. doi: 10.1176/appi.psy.48.5.400. [DOI] [PubMed] [Google Scholar]
  • 16.Huntington’s Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72:971–983. doi: 10.1016/0092-8674(93)90585-E. [DOI] [PubMed] [Google Scholar]
  • 17.Ferrante RJ, Kowall NW, Richardson EP. Proliferative and degenerative changes in striatal spiny neurons in Huntington’s disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry. J Neurosci. 1991;11:3877–3887. doi: 10.1523/JNEUROSCI.11-12-03877.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Sorrel A, Williams RS, Kaufmann WE, Myers RH. Evidence for neuronal degeneration and dendritic plasticity in cortical pyramidal neurons of Huntington’ s disease: a quantitative Golgi study. Neurology. 1993;43:2088–2096. doi: 10.1212/wnl.43.10.2088. [DOI] [PubMed] [Google Scholar]
  • 19.Hersch S, Ferrante R. Neuropathology and pathophysiology of Huntington’s disease. In: Watts R, Koller W, editors. Movement disorders: neurologic principles and practice. 1st ed. New York: McGraw-Hill; 1997. pp. 503–526. [Google Scholar]
  • 20.Rosas HD, Liu AK, Hersch S, et al. Regional and progressive thinning of the cortical ribbon in Huntington’s disease. Neurology. 2002;58:695–701. doi: 10.1212/wnl.58.5.695. [DOI] [PubMed] [Google Scholar]
  • 21.Rosas HD, Hevelone ND, Zaleta AK, Greve DN, Salat DH, Fischl B. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology. 2005;65:745–747. doi: 10.1212/01.wnl.0000174432.87383.87. [DOI] [PubMed] [Google Scholar]
  • 22.Aylward EH, Codori AM, Barta PE, Pearlson GD, Harris GJ, Brandt J. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol. 1996;53:1293–1296. doi: 10.1001/archneur.1996.00550120105023. [DOI] [PubMed] [Google Scholar]
  • 23.Aylward EH, Codori AM, Rosenblatt A, et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington’s disease. Mov Disord. 2000;15:552–560. doi: 10.1002/1531-8257(200005)15:3<552::AID-MDS1020>3.0.CO;2-P. [DOI] [PubMed] [Google Scholar]
  • 24.Borovecki F, Lovrecic L, Zhou J, et al. Genome-wide expression profiling of human blood reveals biomarkers for Huntington’s disease. Proc Natl Acad Sci U S A. 2005;102:11023–11028. doi: 10.1073/pnas.0504921102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Gómez-Tortosa E, MacDonald ME, Friend JC, et al. Quantitative neuropathological changes in presymptomatic Huntington’s disease. Ann Neurol. 2001;49:29–34. doi: 10.1002/1531-8249(200101)49:1<29::AID-ANA7>3.0.CO;2-B. [DOI] [PubMed] [Google Scholar]
  • 26.Paulsen JS, Zimbelman JL, Hinton SC, et al. fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington’s disease. AJNR Am J Neuroradiol. 2004;25:1715–1721. [PMC free article] [PubMed] [Google Scholar]
  • 27.Reading SA, Dziorny AC, Peroutka LA, et al. Functional brain changes in presymptomatic Huntington’s disease. Ann Neurol. 2004;55:879–883. doi: 10.1002/ana.20121. [DOI] [PubMed] [Google Scholar]
  • 28.Rosas HD, Tuch DS, Hevelone ND, et al. Diffusion tensor imaging in presymptomatic and early Huntington’s disease: selective white matter pathology and its relationship to clinical measures. Mov Disord. 2006;21:1317–1325. doi: 10.1002/mds.20979. [DOI] [PubMed] [Google Scholar]
  • 29.Huntington Study Group PHAROS Investigators At risk for Huntington disease: the PHAROS (Prospective Huntington At Risk Observational Study) cohort enrolled. Arch Neurol. 2006;63:991–996. doi: 10.1001/archneur.63.7.991. [DOI] [PubMed] [Google Scholar]
  • 30.Aylward EH. Change in MRI striatal volumes as a biomarker in preclinical Huntington’s disease. Brain Res Bull. 2007;72:152–158. doi: 10.1016/j.brainresbull.2006.10.028. [DOI] [PubMed] [Google Scholar]
  • 31.Julien CL, Thompson JC, Wild S, et al. Psychiatric disorders in preclinical Huntington’s disease. J Neurol Neurosurg Psychiatry. 2007;78:939–943. doi: 10.1136/jnnp.2006.103309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Marshall J, White K, Weaver M, et al. Specific psychiatric manifestations among preclinical Huntington disease mutation carriers. Arch Neurol. 2007;64:116–121. doi: 10.1001/archneur.64.1.116. [DOI] [PubMed] [Google Scholar]
  • 33.Duff K, Paulsen JS, Beglinger LJ, Langbehn DR, Stout JC, Predict-HD Investigators of the Huntington Study Group Psychiatric symptoms in Huntington’s disease before diagnosis: the Predict-HD Study. Biol Psychiatry. 2007;62:1341–1346. doi: 10.1016/j.biopsych.2006.11.034. [DOI] [PubMed] [Google Scholar]
  • 34.Klepac N, Relja M, Klepac R, Hećimović S, Babić T, Trkulja V. Oxidative stress parameters in plasma of Huntington’s disease patients, asymptomatic Huntington’s disease gene carriers and healthy subjects: a cross-sectional study. J Neurol. 2007;254:1676–1683. doi: 10.1007/s00415-007-0611-y. [DOI] [PubMed] [Google Scholar]
  • 35.Saft C, Zange J, Andrich J, et al. Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington’s disease. Mov Disord. 2005;20:674–679. doi: 10.1002/mds.20373. [DOI] [PubMed] [Google Scholar]
  • 36.Varani K, Abbracchio MP, Cannella M, et al. Aberrant A2A receptor function in peripheral blood cells in Huntington’s disease. FASEB J. 2003;17:2148–2150. doi: 10.1096/fj.03-0079fje. [DOI] [PubMed] [Google Scholar]
  • 37.Paulsen JS, Hayden M, Stout JC, et al. Predict-HD Investigators of the Huntington Study Group. Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol. 2006;63:883–890. doi: 10.1001/archneur.63.6.883. [DOI] [PubMed] [Google Scholar]
  • 38.Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length. Clin Genet. 2004;65:267–277. doi: 10.1111/j.1399-0004.2004.00241.x. [DOI] [PubMed] [Google Scholar]
  • 39.Langbehn DR, Paulsen JS. Predictors of diagnosis in Huntington disease. Neurology. 2007;68:1710–1717. doi: 10.1212/01.wnl.0000261918.90053.96. [DOI] [PubMed] [Google Scholar]
  • 40.Tibben A, Niermeijer MF, Roos RA, et al. Understanding the low uptake of presymptomatic DNA testing for Huntington’s disease. Lancet. 1992;340:1416–1416. doi: 10.1016/0140-6736(92)92610-R. [DOI] [PubMed] [Google Scholar]
  • 41.Penziner E, Williams JK, Erwin C, et al. Perceptions of discrimination among persons who have undergone predictive testing for Huntington’s disease. Am J Med Genet B Neuropsychiatr Genet 2007 Oct 19 [Epub ahead of print]. [DOI] [PMC free article] [PubMed]
  • 42.Lilani A. Ethical issues and policy analysis for genetic testing: Huntington’s disease as a paradigm for diseases with a late onset. Hum Reprod Genet Ethics. 2005;11:28–34. doi: 10.1179/hrge.11.2.e35336gt18776032. [DOI] [PubMed] [Google Scholar]
  • 43.Robins Wahlin TB. To know or not to know: a review of behaviour and suicidal ideation in preclinical Huntington’s disease. Patient Educ Couns. 2007;65:279–287. doi: 10.1016/j.pec.2006.08.009. [DOI] [PubMed] [Google Scholar]
  • 44.Timman R, Roos R, Maat-Kievit A, Tibben A. Adverse effects of predictive testing for Huntington disease underestimated: long-term effects 7–10 years after the test. Health Psychol. 2004;23:189–197. doi: 10.1037/0278-6133.23.2.189. [DOI] [PubMed] [Google Scholar]
  • 45.Marder K, Zhao H, Myers RH, Huntington Study Group et al. Rate of functional decline in Huntington’s disease. Neurology. 2000;54:452–458. doi: 10.1212/wnl.54.2.452. [DOI] [PubMed] [Google Scholar]
  • 46.NINDS NET-PD Investigators A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology. 2006;66:664–671. doi: 10.1212/01.wnl.0000201252.57661.e1. [DOI] [PubMed] [Google Scholar]
  • 47.Witjes-Ané MN, Mertens B, van Vugt JP, Bachoud-Lévi AC, van Ommen GJ, Roos RA. Longitudinal evaluation of “presymptomatic” carriers of Huntington’s disease. J Neuropsychiatry Clin Neurosci. 2007;19:310–317. doi: 10.1176/jnp.2007.19.3.310. [DOI] [PubMed] [Google Scholar]
  • 48.DiFiglia M, Sapp E, Chase K, et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron. 1995;14:1075–1081. doi: 10.1016/0896-6273(95)90346-1. [DOI] [PubMed] [Google Scholar]
  • 49.Gutekunst CA, Li SH, Yi H, Ferrante RJ, Li XJ, Hersch SM. The cellular and subcellular localization of huntingtin-associated protein 1 (HAP1): comparison with huntingtin in rat and human. J Neurosci. 1998;18:7674–7686. doi: 10.1523/JNEUROSCI.18-19-07674.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Persichetti F, Ambrose CM, Ge P, et al. Normal and expanded Huntington’s disease gene alleles produce distinguishable proteins due to translation across the CAG repeat. Mol Med. 1995;1:374–383. [PMC free article] [PubMed] [Google Scholar]
  • 51.Sharp AH, Loev SJ, Schilling G, et al. Widespread expression of Huntington’s disease gene (IT15) protein product. Neuron. 1995;14:1065–1074. doi: 10.1016/0896-6273(95)90345-3. [DOI] [PubMed] [Google Scholar]
  • 52.Trottier Y, Devys D, Imbert G, et al. Cellular localization of the Huntington’s disease protein and discrimination of the normal and mutated form. Nat Genet. 1995;10:104–110. doi: 10.1038/ng0595-104. [DOI] [PubMed] [Google Scholar]
  • 53.Cattaneo E, Rigamonti D, Goffredo D, Zuccato C, Squitieri F, Sipione S. Loss of normal huntingtin function: new developments in Huntington’s disease research. Trends Neurosci. 2001;24:182–188. doi: 10.1016/S0166-2236(00)01721-5. [DOI] [PubMed] [Google Scholar]
  • 54.Cattaneo E, Zuccato C, Tartari M. Normal huntingtin function: an alternative approach to Huntington’s disease. Nat Rev Neurosci. 2005;6:919–930. doi: 10.1038/nrn1806. [DOI] [PubMed] [Google Scholar]
  • 55.Zuccato C, Ciammola A, Rigamonti D, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington’s disease. Science. 2001;293:493–498. doi: 10.1126/science.1059581. [DOI] [PubMed] [Google Scholar]
  • 56.Goldberg YP, Nicholson DW, Rasper DM, et al. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat Genet. 1996;13:442–449. doi: 10.1038/ng0896-442. [DOI] [PubMed] [Google Scholar]
  • 57.Wellington CL, Brinkman RR, O’Kusky JR, Hayden MR. Toward understanding the molecular pathology of Huntington’s disease. Brain Pathol. 1997;7:979–1002. doi: 10.1111/j.1750-3639.1997.tb00897.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Wellington CL, Ellerby LM, Gutekunst CA, et al. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington’s disease. J Neurosci. 2002;22:7862–7872. doi: 10.1523/JNEUROSCI.22-18-07862.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Hoffner G, Island ML, Djian P. Purification of neuronal inclusions of patients with Huntington’s disease reveals a broad range of N-terminal fragments of expanded huntingtin and insoluble polymers. J Neurochem. 2005;95:125–136. doi: 10.1111/j.1471-4159.2005.03348.x. [DOI] [PubMed] [Google Scholar]
  • 60.Graham RK, Deng Y, Slow EJ, et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell. 2006;125:1179–1191. doi: 10.1016/j.cell.2006.04.026. [DOI] [PubMed] [Google Scholar]
  • 61.Kaltenbach LS, Romero E, Becklin RR, et al. Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet. 2007;3:e82–e82. doi: 10.1371/journal.pgen.0030082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Smith KM, Matson S, Matson WR, et al. Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington’s disease mice. Biochim Biophys Acta. 2006;1762:616–626. doi: 10.1016/j.bbadis.2006.03.004. [DOI] [PubMed] [Google Scholar]
  • 63.McGill JK, Beal MF. PGC-1α, a new therapeutic target in Huntington’s disease? Cell. 2006;127:465–468. doi: 10.1016/j.cell.2006.10.023. [DOI] [PubMed] [Google Scholar]
  • 64.Ryu H, Rosas HD, Hersch SM, Ferrante RJ. The therapeutic role of creatine in Huntington’s disease. Pharmacol Ther. 2005;108:193–207. doi: 10.1016/j.pharmthera.2005.04.008. [DOI] [PubMed] [Google Scholar]
  • 65.Browne SE, Beal MF. Oxidative damage in Huntington’s disease pathogenesis. Antioxid Redox Signal. 2006;8:2061–2073. doi: 10.1089/ars.2006.8.2061. [DOI] [PubMed] [Google Scholar]
  • 66.Altmann SM, Muryshev A, Fossale E, et al. Discovery of bioactive small-molecule inhibitor of poly ADP-ribose polymerase: implications for energy-deficient cells. Chem Biol. 2006;13:765–770. doi: 10.1016/j.chembiol.2006.05.012. [DOI] [PubMed] [Google Scholar]
  • 67.Kovtun IV, Liu Y, Bjoras M, Klungland A, Wilson SH, McMurray CT. OGG1 initiates age-dependent CAG trinucleotide expansion in somatic cells. Nature. 2007;447:447–452. doi: 10.1038/nature05778. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Stack EC, Dedeoglu A, Smith KM, et al. Neuroprotective effects of synaptic modulation in Huntington’s disease R6/2 mice. J Neurosci. 2007;27:12908–12915. doi: 10.1523/JNEUROSCI.4318-07.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Cepeda C, Hurst RS, Calvert CR, et al. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington’s disease. J Neurosci. 2003;23:961–969. doi: 10.1523/JNEUROSCI.23-03-00961.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Pattison LR, Kotter MR, Fraga D, Bonelli RM. Apoptotic cascades as possible targets for inhibiting cell death in Huntington’ s disease. J Neurol. 2006;253:1137–1142. doi: 10.1007/s00415-006-0198-8. [DOI] [PubMed] [Google Scholar]
  • 71.Davies SW, Turmaine M, Cozens BA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 1997;90:537–548. doi: 10.1016/S0092-8674(00)80513-9. [DOI] [PubMed] [Google Scholar]
  • 72.DiFiglia M, Sapp E, Chase KO, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 1997;277:1990–1993. doi: 10.1126/science.277.5334.1990. [DOI] [PubMed] [Google Scholar]
  • 73.Gutekunst CA, Li SH, Yi H, et al. Nuclear and neuropil aggregates in Huntington’s disease: relationship to neuropathology. J Neurosci. 1999;19:2522–2534. doi: 10.1523/JNEUROSCI.19-07-02522.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Jana NR, Zemskov EA, Wang G, Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet. 2001;10:1049–1059. doi: 10.1093/hmg/10.10.1049. [DOI] [PubMed] [Google Scholar]
  • 75.Sarkar S, Perlstein EO, Imarisio S, et al. Small molecules enhance autophagy and reduce toxicity in Huntington’s disease models. Nat Chem Biol. 2007;3:331–338. doi: 10.1038/nchembio883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Ventruti A, Cuervo AM. Autophagy and neurodegeneration. Curr Neurol Neurosci Rep. 2007;7:443–451. doi: 10.1007/s11910-007-0068-5. [DOI] [PubMed] [Google Scholar]
  • 77.Floto RA, Sarkar S, Perlstein EO, Kampmann B, Schreiber SL, Rubinsztein DC. Small molecule enhancers of rapamycin-induced TOR inhibition promote autophagy, reduce toxicity in Huntington’s disease models and enhance killing of mycobacteria by macrophages. Autophagy. 2007;3:620–622. doi: 10.4161/auto.4898. [DOI] [PubMed] [Google Scholar]
  • 78.Yamamoto A, Cremona ML, Rothman JE. Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway. J Cell Biol. 2006;172:719–731. doi: 10.1083/jcb.200510065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Ravikumar B, Rubinsztein DC. Role of autophagy in the clearance of mutant huntingtin: a step towards therapy? Mol Aspects Med. 2006;27:520–527. doi: 10.1016/j.mam.2006.08.008. [DOI] [PubMed] [Google Scholar]
  • 80.Seo H, Sonntag KC, Kim W, Cattaneo E, Isacson O. Proteasome activator enhances survival of Huntington’s disease neuronal model cells. PLoS ONE. 2007;2:e238–e238. doi: 10.1371/journal.pone.0000238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Bennett EJ, Shaler TA, Woodman B, et al. Global changes to the ubiquitin system in Huntington’s disease. Nature. 2007;448:704–708. doi: 10.1038/nature06022. [DOI] [PubMed] [Google Scholar]
  • 82.Howard RA, Sharma P, Hajjar C, et al. Ubiquitin conjugating enzymes participate in polyglutamine protein aggregation. BMC Cell Biol. 2007;8:32–32. doi: 10.1186/1471-2121-8-32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Zuccato C, Belyaev N, Conforti P, et al. Widespread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington’s disease. J Neurosci. 2007;27:6972–6983. doi: 10.1523/JNEUROSCI.4278-06.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Strand AD, Baquet ZC, Aragaki AK, et al. Expression profiling of Huntington’s disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J Neurosci. 2007;27:11758–11768. doi: 10.1523/JNEUROSCI.2461-07.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Zuccato C, Liber D, Ramos C, et al. Progressive loss of BDNF in a mouse model of Huntington’s disease and rescue by BDNF delivery. Pharmacol Res. 2005;52:133–139. doi: 10.1016/j.phrs.2005.01.001. [DOI] [PubMed] [Google Scholar]
  • 86.Dompierre JP, Godin JD, Charrin BC, et al. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington’s disease by increasing tubulin acetylation. J Neurosci. 2007;27:3571–3583. doi: 10.1523/JNEUROSCI.0037-07.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Hersch SM. Huntington’s disease: prospects for neuroprotective therapy 10 years after the discovery of the causative genetic mutation. Curr Opin Neurol. 2003;16:501–506. doi: 10.1097/00019052-200308000-00010. [DOI] [PubMed] [Google Scholar]
  • 88.Yang W, Dunlap JR, Andrews RB, Wetzel R. Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum Mol Genet. 2002;11:2905–2917. doi: 10.1093/hmg/11.23.2905. [DOI] [PubMed] [Google Scholar]
  • 89.Schilling G, Savonenko AV, Klevytska A, et al. Nuclear-targeting of mutant huntingtin fragments produces Huntington’s disease-like phenotypes in transgenic mice. Hum Mol Genet. 2004;13:1599–1610. doi: 10.1093/hmg/ddh175. [DOI] [PubMed] [Google Scholar]
  • 90.Boutell JM, Thomas P, Neal JW, et al. Aberrant interactions of transcriptional repressor proteins with the Huntington’s disease gene product, huntingtin. Hum Mol Genet. 1999;8:1647–1655. doi: 10.1093/hmg/8.9.1647. [DOI] [PubMed] [Google Scholar]
  • 91.Dunah AW, Jeong H, Griffin A, et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington’ s disease. Science. 2002;296:2238–2243. doi: 10.1126/science.1072613. [DOI] [PubMed] [Google Scholar]
  • 92.Holbert S, Denghien I, Kiechle T, et al. The Gln-A1a repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington’s disease pathogenesis. Proc Natl Acad Sci U S A. 2001;98:1811–1816. doi: 10.1073/pnas.041566798. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Nucifora FC, Sasaki M, Peters MF, et al. Interference by huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity. Science. 2001;291:2423–2428. doi: 10.1126/science.1056784. [DOI] [PubMed] [Google Scholar]
  • 94.Steffan JS, Bodai L, Pallos J, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature. 2001;413:739–743. doi: 10.1038/35099568. [DOI] [PubMed] [Google Scholar]
  • 95.Steffan JS, Kazantsev A, Spasic-Boskovic O, et al. The Huntington’s disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A. 2000;97:6763–6768. doi: 10.1073/pnas.100110097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.McCampbell A, Taylor JP, Taye AA, et al. CREB-binding protein sequestration by expanded polyglutamine. Hum Mol Genet. 2000;9:2197–2202. doi: 10.1093/hmg/9.14.2197. [DOI] [PubMed] [Google Scholar]
  • 97.Sadri-Vakili G, Bouzou B, Benn CL, et al. Histones associated with downregulated genes are hypo-acetylated in Huntington’s disease models. Hum Mol Genet. 2007;16:1293–1306. doi: 10.1093/hmg/ddm078. [DOI] [PubMed] [Google Scholar]
  • 98.Stack EC, Del Signore SJ, Luthi-Carter R, et al. Modulation of nucleosome dynamics in Huntington’s disease. Hum Mol Genet. 2007;16:1164–1175. doi: 10.1093/hmg/ddm064. [DOI] [PubMed] [Google Scholar]
  • 99.Kazantsev AG, Hersch SM. Drug targeting of dysregulated transcription in Huntington’s disease. Prog Neurobiol. 2007;83:249–259. doi: 10.1016/j.pneurobio.2007.02.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Sadri-Vakili G, Cha JH. Mechanisms of disease: histone modifications in Huntington’s disease. Nat Clin Pract Neurol. 2006;2:330–338. doi: 10.1038/ncpneuro0199. [DOI] [PubMed] [Google Scholar]
  • 101.Butler R, Bates GP. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat Rev Neurosci. 2006;7:784–796. doi: 10.1038/nrn1989. [DOI] [PubMed] [Google Scholar]
  • 102.DiFiglia M, Sena-Esteves M, Chase K, et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A. 2007;104:17204–17209. doi: 10.1073/pnas.0708285104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Denovan-Wright EM, Davidson BL. RNAi: a potential therapy for the dominantly inherited nucleotide repeat diseases. Gene Ther. 2006;13:525–531. doi: 10.1038/sj.gt.3302664. [DOI] [PubMed] [Google Scholar]
  • 104.Miller TW, Messer A. Intrabody applications in neurological disorders: progress and future prospects. Mol Ther. 2005;12:394–401. doi: 10.1016/j.ymthe.2005.04.003. [DOI] [PubMed] [Google Scholar]
  • 105.Coufal M, Maxwell MM, Russel DE, et al. Discovery of a novel small-molecule targeting selective clearance of mutant huntingtin fragments. J Biomol Screen. 2007;12:351–360. doi: 10.1177/1087057107299428. [DOI] [PubMed] [Google Scholar]
  • 106.Valera AG, Diaz-Hernandez M, Hernandez F, Ortega Z, Lucas JJ. The ubiquitin-proteasome system in Huntington’s disease. Neuroscientist. 2005;11:583–594. doi: 10.1177/1073858405280639. [DOI] [PubMed] [Google Scholar]
  • 107.Brignull HR, Morley JF, Morimoto RI. The stress of misfolded proteins: C. elegans models for neurodegenerative disease and aging. Adv Exp Med Biol. 2007;594:167–189. doi: 10.1007/978-0-387-39975-1_15. [DOI] [PubMed] [Google Scholar]
  • 108.Ferrante RJ, Andreassen OA, Dedeoglu A, et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington’s disease. J Neurosci. 2002;22:1592–1599. doi: 10.1523/JNEUROSCI.22-05-01592.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 109.Andreassen OA, Dedeoglu A, Ferrante RJ, et al. Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington’s disease. Neurobiol Dis. 2001;8:479–491. doi: 10.1006/nbdi.2001.0406. [DOI] [PubMed] [Google Scholar]
  • 110.Ferrante RJ, Andreassen OA, Jenkins BG, et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington’s disease. J Neurosci. 2000;20:4389–4397. doi: 10.1523/JNEUROSCI.20-12-04389.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 111.Andreassen OA, Ferrante RJ, Huang HM, et al. Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington’s disease. Ann Neurol. 2001;50:112–117. doi: 10.1002/ana.1085. [DOI] [PubMed] [Google Scholar]
  • 112.Andreassen OA, Ferrante RJ, Dedeoglu A, Beal MF. Lipoic acid improves survival in transgenic mouse models of Huntington’s disease. Neuroreport. 2001;12:3371–3373. doi: 10.1097/00001756-200110290-00044. [DOI] [PubMed] [Google Scholar]
  • 113.Chen M, Ona VO, Li M, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000;6:797–801. doi: 10.1038/80538. [DOI] [PubMed] [Google Scholar]
  • 114.Dedeoglu A, Kubilus JK, Jeitner TM, et al. Therapeutic effects of cystamine in a murine model of Huntington’s disease. J Neurosci. 2002;22:8942–8950. doi: 10.1523/JNEUROSCI.22-20-08942.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 115.Karpuj MV, Garren H, Slunt H, et al. Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington’s disease brain nuclei. Proc Natl Acad Sci U S A. 1999;96:7388–7393. doi: 10.1073/pnas.96.13.7388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 116.Nguyen T, Hamby A, Massa SM. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington’s disease mouse model. Proc Natl Acad Sci U S A. 2005;102:11840–11845. doi: 10.1073/pnas.0502177102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 117.Youdim MB, Stephenson G, Ben Shachar D. Ironing iron out in Parkinson’s disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci. 2004;1012:306–325. doi: 10.1196/annals.1306.025. [DOI] [PubMed] [Google Scholar]
  • 118.Landwehrmeyer GB, Dubois B, de Yebenes JG, et al. Riluzole in Huntington’s disease: a 3-year, randomized controlled study. Ann Neurol. 2007;62:262–272. doi: 10.1002/ana.21181. [DOI] [PubMed] [Google Scholar]
  • 119.Rosas HD, Koroshetz WJ, Jenkins BG, et al. Riluzole therapy in Huntington’s disease (HD) Mov Disord. 1999;14:326–330. doi: 10.1002/1531-8257(199903)14:2<326::AID-MDS1019>3.0.CO;2-Q. [DOI] [PubMed] [Google Scholar]
  • 120.Duan W, Guo Z, Jiang H, et al. Paroxetine retards disease onset and progression in Huntingtin mutant mice. Ann Neurol. 2004;55:590–594. doi: 10.1002/ana.20075. [DOI] [PubMed] [Google Scholar]
  • 121.Hockly E, Richon VM, Woodman B, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington’s disease. Proc Natl Acad Sci U S A. 2003;100:2041–2046. doi: 10.1073/pnas.0437870100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 122.Ferrante RJ, Kubilus JK, Lee J, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington’s disease mice. J Neurosci. 2003;23:9418–9427. doi: 10.1523/JNEUROSCI.23-28-09418.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 123.Ferrante RJ, Ryu H, Kubilus JK, et al. Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington’s disease. J Neurosci. 2004;24:10335–10342. doi: 10.1523/JNEUROSCI.2599-04.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 124.Gardian G, Browne SE, Choi DK, et al. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington’s disease. J Biol Chem. 2005;280:556–563. doi: 10.1074/jbc.M410210200. [DOI] [PubMed] [Google Scholar]
  • 125.Keene CD, Rodrigues CM, Eich T, Chhabra MS, Steer CJ, Low WC. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington’s disease. Proc Natl Acad Sci U S A. 2002;99:10671–10676. doi: 10.1073/pnas.162362299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 126.Zuccato C, Cattaneo E. Role of brain-derived neurotrophic factor in Huntington’s disease. Prog Neurobiol. 2007;81:294–330. doi: 10.1016/j.pneurobio.2007.01.003. [DOI] [PubMed] [Google Scholar]
  • 127.Ranen NG, Peyser CE, Coyle JT, et al. A controlled trial of idebenone in Huntington’s disease. Mov Disord. 1996;11:549–554. doi: 10.1002/mds.870110510. [DOI] [PubMed] [Google Scholar]
  • 128.Peyser CE, Folstein M, Chase GA, et al. Trial of d-alpha-tocopherol in Huntington’s disease. Am J Psychiatry. 1995;152:1771–1775. doi: 10.1176/ajp.152.12.1771. [DOI] [PubMed] [Google Scholar]
  • 129.Huntington Study Group Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington’s disease. Neurology. 1998;50:1366–1373. doi: 10.1212/wnl.50.5.1366. [DOI] [PubMed] [Google Scholar]
  • 130.Tabrizi SJ, Blamire AM, Manners DN, et al. High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study. Neurology. 2005;64:1655–1656. doi: 10.1212/01.WNL.0000160388.96242.77. [DOI] [PubMed] [Google Scholar]
  • 131.Hersch SM, Gevorkian S, Marder K, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG. Neurology. 2006;66:250–252. doi: 10.1212/01.wnl.0000194318.74946.b6. [DOI] [PubMed] [Google Scholar]
  • 132.Huntington Study Group A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology. 2001;57:397–404. doi: 10.1212/wnl.57.3.397. [DOI] [PubMed] [Google Scholar]
  • 133.Dubinsky R, Gray C. CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington’s disease. Mov Disord. 2006;21:530–533. doi: 10.1002/mds.20756. [DOI] [PubMed] [Google Scholar]
  • 134.Puri BK, Leavitt BR, Hayden MR, et al. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology. 2005;65:286–292. doi: 10.1212/01.wnl.0000169025.09670.6d. [DOI] [PubMed] [Google Scholar]
  • 135.Kremer B, Clark C, Hardy M, Almqvist E, Raymond L, Hayden M. Lamotrigine does not retard the progression of Huntington’s disease. WFN Working Group on Huntington’s Disease 1997:34.
  • 136.Huntington Study Group Dosage effects of riluzole in Huntington’s disease: a multicenter placebo-controlled study. Neurology. 2003;61:1551–1556. doi: 10.1212/01.wnl.0000096019.71649.2b. [DOI] [PubMed] [Google Scholar]
  • 137.Seppi K, Mueller J, Bodner T, et al. Riluzole in Huntington’s disease (HD): an open label study with one year follow up. J Neurol. 2001;248:866–869. doi: 10.1007/s004150170071. [DOI] [PubMed] [Google Scholar]

Articles from Neurotherapeutics are provided here courtesy of Elsevier

RESOURCES